Table 2.
Characteristics of included studies.
| Study | Year | Country | Design | Patients | Age | Gender (M/F) | Tumor size | Quality score (0–9) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LRPS | ORPS | LRPS | ORPS | LRPS | ORPS | |||||||
| Dilai Luo | 2020 | China | Retrospective | 23 | 25 | 56 ± 13 | 59 ± 11 | 15/8 | 18/7 | 3.2 ± 0.7 | 3.3 ± 0.6 | 7 |
| Nicky van der Heijde | 2020 | Europe | Retrospective | 150 | 150 | 64.5 ± 13.8 | 64.2 ± 13.5 | 87/63 | 85/65 | 49 ± 26 | 54/28 | 7 |
| Jinsoo Rhu | 2018 | Korea | Retrospective | 53 | 97 | 58.0 ± 8.8 | 58.2 ± 9.4 | 43/10 | 81/16 | 3.1 ± 1.8 | 3.1 ± 1.7 | 8 |
| Jai Young Cho | 2015 | Korea | Retrospective | 24 | 19 | 53.9 ± 12.6 | 60.0 ± 8.9 | 17/7 | 16/3 | 3.7 ± 1.8 | 4.8 ± 2.5 | 7 |